

ASX Release

5 April 2022

ANAGRELIDE PATENT FOR THE UNITED STATES

MELBOURNE, AUSTRALIA 5 April 2022: Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company focused on developing its invariant Natural Killer T (iNKT) cell platform to treat blood cancers and a leader in oro-mucosal drug delivery, is pleased to announce that the US Patent and Trademark Office (USPTO) has now accepted its patent application covering anagrelide and the patent will proceed to grant.

The USPTO will grant Arovella's Application No. 15/538,326 titled "Use of Anagrelide for Treating Cancer". The patent has an expiry of December 2035 and it adds to the granted patents in Europe, Japan and Australia.

As previously announced (22 September 2020), anagrelide is being developed for the treatment of metastatic disease in patients who have certain solid tumour cancers. Clinical experience has shown that increased platelet numbers associated with several solid tumour cancers decreases progression-free life expectancy. Anagrelide not only advantageously lowers blood platelets, but it has also been shown to inhibit cancer cell movement towards platelet-producing cells, megakaryocytes, principally found in the bone marrow but also the lung, two likely sites of metastases.

Arovella is actively seeking to find co-development partners to fund ongoing research or to out-licence the anagrelide intellectual property to entities focused on development of cancer therapies, where increased platelets play a role in the progression of the disease. This includes a number of cancer types, including melanoma, mesothelioma, ovarian, vulvar, cervical, renal cell, lung, glioblastoma, pancreatic, endometrial and colorectal cancer.

Arovella's CEO and MD, Dr Michael Baker, commented: "Receiving the notice that this patent will proceed to grant is incredibly important for the commercial prospects of the technology. The US is a key market for a product of this nature and we now have patents covering a substantial proportion of the globe".

ASX: ALA

Arovella Therapeutics Limited
ACN 090 987 250



For and on behalf of the Board and for further information, please contact:

Dr Michael Baker
Chief Executive Officer & Managing Director
Arovella Therapeutics Ltd
Tel +61 (0) 403 468 187
mbaker@arovella.com

NOTES TO EDITORS:

About Arovella Therapeutics Ltd

Arovella Therapeutics Ltd (ASX: ALA) is a biotechnology company focused on developing therapies to treat human disease. Arovella's two focus areas are oncology and conditions that impact the central nervous system. Arovella is developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers. Arovella is also developing its DKK1-peptide targeting technology licenced from MD Anderson to be used in conjunction with its iNKT cell therapy platform. The Company is developing low-risk oral sprays to reformulate existing pharmaceuticals. The potential benefits of administering drugs through the oral mucosa (i.e. cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. Arovella's product pipeline includes an oral spray for the platelet-lowering drug anagrelide to treat metastatic disease in the background of high platelets, and ZolpiMist™, a first-in-class oral spray of zolpidem tartrate to treat short-term insomnia. ZolpiMist is approved by the FDA, TGA and the Ministry of Health (Chile) and is marketed in the USA. Arovella has rights to the product outside of the US and Canada. Other products in development include oral sprays to treat migraine headaches, motion sickness, and drug-resistant epilepsy.

For more information, visit www.arovella.com

This announcement contains certain statements which may constitute forward-looking statements or information ("forward-looking statements"), including statements regarding negotiations with third parties and regulatory approvals. These forward-looking statements are based on certain key expectations and assumptions, including assumptions regarding actions of third parties and financial terms. These factors and assumptions are based upon currently available information and the forward-looking statements contained herein speak only as of the date hereof. Although the expectations and assumptions reflected in the forward-looking statements are reasonable in the view of the Company's directors and management, reliance should not be placed on such statements as there is no assurance that they will prove correct. This is because forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could influence actual results or events and cause actual results or events to differ materially from those stated, anticipated or implied in the forward-looking statements. These risks include, but are not limited to: uncertainties and other factors that are beyond the control of the Company; global economic conditions; risk associated with foreign currencies; and risk associated with securities market volatility. The Company assumes no obligation to update any forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements, except as required by Australian securities laws and ASX Listing Rules.